The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...